HC Wainwright Comments on SOPHiA GENETICS Q2 Earnings

SOPHiA GENETICS SA (NASDAQ:SOPH) – Equities researchers at HC Wainwright issued their Q2 2026 EPS estimates for shares of SOPHiA GENETICS in a report released on Monday, July 20th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for SOPHiA GENETICS’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.58) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.04 EPS, FY2029 earnings at $0.34 EPS and FY2030 earnings at $0.69 EPS.

A number of other brokerages also recently commented on SOPH. BTIG Research reissued a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of “Moderate Buy” and a consensus price target of $9.00.

SOPHiA GENETICS Stock Down 1.5%

Shares of NASDAQ:SOPH opened at $6.40 on Wednesday. SOPHiA GENETICS has a fifty-two week low of $2.92 and a fifty-two week high of $6.77. The firm’s 50 day moving average price is $5.34 and its 200 day moving average price is $5.06. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The stock has a market cap of $536.90 million, a price-to-earnings ratio of -12.31 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The company had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Insider Activity

In related news, CEO Ross Muken sold 9,838 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the completion of the sale, the chief executive officer owned 670,651 shares in the company, valued at $3,500,798.22. This represents a 1.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.10, for a total transaction of $26,953.50. Following the completion of the transaction, the chief technology officer owned 192,171 shares in the company, valued at approximately $980,072.10. This represents a 2.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 176,711 shares of company stock worth $959,913 over the last 90 days. 4.88% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after purchasing an additional 31,000 shares during the last quarter. Akre Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS during the third quarter worth approximately $49,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $12 price target, suggesting meaningful upside from current levels and boosting sentiment around SOPHiA GENETICS’s longer-term growth story.
• Positive Sentiment: The same research note laid out an improving earnings path, with SOPHiA GENETICS expected to narrow losses in 2026-2027 and turn profitable by FY2028, while projecting stronger earnings in FY2029 and FY2030.
• Neutral Sentiment: The company announced it will report second-quarter 2026 results on August 4, which typically increases trading interest as investors position ahead of the earnings release. SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
• Neutral Sentiment: A media appearance featuring the CEO discussing how AI could personalize patient therapies reinforces the company’s AI-driven precision medicine narrative, but it is not a direct financial catalyst. SOPHiA GENETICS CEO says AI will personalize patient therapies
• Negative Sentiment: The analyst estimates still point to continued losses in the near term, including FY2026 EPS of ($0.58) and FY2027 EPS of ($0.20), which may temper enthusiasm despite the bullish target price.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.